A PHASE III CLINICAL TRIAL TO STUDY THE IMMUNOGENICITY, TOLERABILITY, AND MANUFACTURING CONSISTENCY OF V503 (A MULTIVALENT HUMAN PAPILLOMAVIRUS [HPV] L1 VIRUS-LIKE PRTICLE [VLP] VACCINE) IN PREADOLESCENTS AND ADOLESCENTS (9 TO 15 YEAR OLDS) WITH A COMPARISON TO YOUNG WOMEN (16 TO 26 YEAR OLDS)
Not Applicable
- Registration Number
- PER-120-12
- Lead Sponsor
- MERCK SHARP & DOHME PERU S.R.L.,
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 110
Inclusion Criteria
. SUBJECTS WHO ARE ENROLLED IN PROTOCOL 002 BETWEEN 9 AND 15 YEARS OF AGE AND RECEIVED 3 DOSES OF 9-VALENT HPV L1 VLP VACCINE.
Exclusion Criteria
. SUBJECTS WHO ARE CONCURRENTLY ENROLLED IN CLINICAL STUDIES THAT WOULD INVOLVE OR INTERFERE WITH THE COLLECTION OF GENITAL SPECIMENS.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method